On August 25, 2023, the Board of Design Therapeutics, Inc. appointed Pratik Shah, Ph.D., as the Company?s Chief Executive Officer. Dr. Shah will also continue to serve as Chairperson on the Board. Dr. Shah, age 53, has served as the Company?s Chairperson and a member of the Board since December 2017.

Dr. Shah also serves as the Chairman of the board of directors for ARS Pharmaceuticals, Inc. and has been a member of its board of directors since April 2016. He has also served as President of Marlinspike Group, LLC since August 2018 and of Marlinspike Group, Inc. from June 2015 to October 2020. Dr. Shah served as the Chairman of the board of directors of Synthorx, Inc. from October 2018 until its acquisition by Sanofi S.A. in January 2020.

Dr. Shah also served as the President and Chief Executive Officer and Chairman of the board of directors of Auspex Pharmaceuticals, Inc. from October 2013 until its acquisition by Teva Pharmaceuticals Industries Ltd. in May 2015. From 2004 to 2014, he was a partner at Thomas, McNerney & Partners. Dr. Shah holds a B.S. in Biological Sciences from the University of California at Irvine and a Ph.D. in Biochemistry and Molecular Biology and an M.B.A. in Finance, both from the University of Chicago.

On August 25, 2023, João M.D. Siffert, M.D., and the Board of Directors of Design Therapeutics, Inc. agreed to the resignation of Dr. Siffert from all offices of the company and from the Board, effective immediately, and as an employee of the Company, effective September 1, 2023 (the Separation Date"). Prior to his resignation, Dr. Siffert served as the company's Chief Executive Officer.